These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28202824)

  • 1. [Disease-Modifying Therapy for Parkinson's Disease].
    Shimura H; Hattori N
    Brain Nerve; 2017 Feb; 69(2):159-165. PubMed ID: 28202824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic approaches to target alpha-synuclein pathology.
    Brundin P; Dave KD; Kordower JH
    Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
    Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
    Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation between α-synuclein and microglia in Parkinson's disease: Recent developments.
    Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Neuroscience; 2015 Aug; 302():47-58. PubMed ID: 25684748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pathogenesis of Parkinson's disease.
    Morris HR; Spillantini MG; Sue CM; Williams-Gray CH
    Lancet; 2024 Jan; 403(10423):293-304. PubMed ID: 38245249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases.
    Shannon KM; Keshavarzian A; Dodiya HB; Jakate S; Kordower JH
    Mov Disord; 2012 May; 27(6):716-9. PubMed ID: 22550057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral vectors as a tool to model and treat Parkinson's disease.
    Bensadoun JC; Aebischer P
    Wien Klin Wochenschr; 2006 Oct; 118(19-20):568-70. PubMed ID: 17136329
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.
    Zella MAS; Metzdorf J; Ostendorf F; Maass F; Muhlack S; Gold R; Haghikia A; Tönges L
    Cells; 2019 Jan; 8(2):. PubMed ID: 30708997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal α-synuclein deposits in Parkinson's disease patients and animal models.
    Veys L; Vandenabeele M; Ortuño-Lizarán I; Baekelandt V; Cuenca N; Moons L; De Groef L
    Acta Neuropathol; 2019 Mar; 137(3):379-395. PubMed ID: 30721408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research in motion: the enigma of Parkinson's disease pathology spread.
    Brundin P; Li JY; Holton JL; Lindvall O; Revesz T
    Nat Rev Neurosci; 2008 Oct; 9(10):741-5. PubMed ID: 18769444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
    Bobela W; Aebischer P; Schneider BL
    Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.